HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · IEX Real-Time Price · USD
0.765
+0.058 (8.20%)
At close: Apr 23, 2024, 4:00 PM
0.785
+0.020 (2.60%)
After-hours: Apr 23, 2024, 7:55 PM EDT
HOOKIPA Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for HOOKIPA Pharma stock have an average target of 4.44, with a low estimate of 2.25 and a high estimate of 6.50. The average target predicts an increase of 480.39% from the current stock price of 0.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2024.
Analyst Ratings
The average analyst rating for HOOKIPA Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +553.59% | Mar 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +749.67% | Mar 25, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +553.59% | Jan 30, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $7 | Buy | Reiterates | $7 | +815.03% | Sep 27, 2023 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +422.88% | Sep 6, 2023 |
Financial Forecast
Revenue This Year
33.56M
from 20.13M
Increased by 66.71%
Revenue Next Year
15.23M
from 33.56M
Decreased by -54.62%
EPS This Year
-0.36
from -0.86
EPS Next Year
-0.52
from -0.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 76.1M | 26.3M | 15.8M | 206.6M | 396.1M |
| Avg | 33.6M | 15.2M | 6.0M | 133.0M | 281.2M |
| Low | 7.8M | 7.7M | n/a | 62.8M | 170.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 278.2% | -21.8% | 3.4% | 3,372.6% | 197.7% |
| Avg | 66.7% | -54.6% | -60.9% | 2,135.6% | 111.4% |
| Low | -61.1% | -76.9% | - | 954.8% | 28.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.04 | -0.39 | -0.46 | -0.30 | 0.67 |
| Avg | -0.36 | -0.52 | -0.67 | -0.33 | 0.47 |
| Low | -0.59 | -0.71 | -0.83 | -0.35 | 0.28 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.